open access

Vol 51, No 1 (2013)
Original paper
Submitted: 2013-04-28
Accepted: 2013-04-28
Published online: 2013-04-24
Get Citation

Expression of CD200 and CD200R regulatory molecules on the CD83+ monocyte-derived dendritic cells generated from patients with laryngeal cancer

Janusz Klatka, Ewelina Grywalska, Maria Klatka, Mansur Rahnama, Agnieszka Polak, Jacek Rolinski
DOI: 10.5603/FHC.2013.009
·
Folia Histochem Cytobiol 2013;51(1):59-65.

open access

Vol 51, No 1 (2013)
ORIGINAL PAPERS
Submitted: 2013-04-28
Accepted: 2013-04-28
Published online: 2013-04-24

Abstract

CD200 molecule may play a role in local tumor invasion and augmenting the metastatic capacity of squamous cell carcinoma. The objective of the study was to assess by means of flow cytometry the expression of CD200 and its receptor, CD200R, on CD83+ monocyte-derived dendritic cells (Mo-DCs), pulsed or not with autologous tumor cell lysates (aTCL) in patients who suffer from laryngeal carcinoma in comparison to healthy donors. The median value of CD200 mean fluorescence intensity (MFI) on the Mo-DCs pulsed with aTCL of the patients with laryngeal cancer was 61.94 and was statistically significantly higher than on the unpulsed Mo-DCs of these patients (24.81) and healthy donors (16.63), p = 0.0034 and p = 0.0004, respectively. Median MFI score of CD200R in specimen derived from patients with laryngeal cancer was 259.31 on Mo-DCs pulsed with aTCL, while in unpulsed Mo-DCs was 86.74 (p = 0.0035) and on the Mo-DCs from control group it was 67.51 (p = 0.0004). The obtained results showed a relation between the presence of laryngeal cancer and the expression of CD200 and CD200R molecules on the CD83+ Mo-DCs pulsed with autologous cancer cell lysates. This analysis may have implications for setting new therapeutic options for cancer immunotherapy in the future. (Folia Histochemica et Cytobiologica 2013, Vol. 51, No. 1, 59–65)

Abstract

CD200 molecule may play a role in local tumor invasion and augmenting the metastatic capacity of squamous cell carcinoma. The objective of the study was to assess by means of flow cytometry the expression of CD200 and its receptor, CD200R, on CD83+ monocyte-derived dendritic cells (Mo-DCs), pulsed or not with autologous tumor cell lysates (aTCL) in patients who suffer from laryngeal carcinoma in comparison to healthy donors. The median value of CD200 mean fluorescence intensity (MFI) on the Mo-DCs pulsed with aTCL of the patients with laryngeal cancer was 61.94 and was statistically significantly higher than on the unpulsed Mo-DCs of these patients (24.81) and healthy donors (16.63), p = 0.0034 and p = 0.0004, respectively. Median MFI score of CD200R in specimen derived from patients with laryngeal cancer was 259.31 on Mo-DCs pulsed with aTCL, while in unpulsed Mo-DCs was 86.74 (p = 0.0035) and on the Mo-DCs from control group it was 67.51 (p = 0.0004). The obtained results showed a relation between the presence of laryngeal cancer and the expression of CD200 and CD200R molecules on the CD83+ Mo-DCs pulsed with autologous cancer cell lysates. This analysis may have implications for setting new therapeutic options for cancer immunotherapy in the future. (Folia Histochemica et Cytobiologica 2013, Vol. 51, No. 1, 59–65)

Get Citation

Keywords

CD200; CD200R; monocyte-derived dendritic cells; cell lysates; laryngeal cancer

About this article
Title

Expression of CD200 and CD200R regulatory molecules on the CD83+ monocyte-derived dendritic cells generated from patients with laryngeal cancer

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 51, No 1 (2013)

Article type

Original paper

Pages

59-65

Published online

2013-04-24

DOI

10.5603/FHC.2013.009

Bibliographic record

Folia Histochem Cytobiol 2013;51(1):59-65.

Keywords

CD200
CD200R
monocyte-derived dendritic cells
cell lysates
laryngeal cancer

Authors

Janusz Klatka
Ewelina Grywalska
Maria Klatka
Mansur Rahnama
Agnieszka Polak
Jacek Rolinski

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl